Pediatric Obesity GLP-1: 5 Key Clinical Insights
A synthesis of the evidence on semaglutide and liraglutide for adolescent obesity, set against the AAP 2023 Clinical Practice Guideline and emerging real-world data.
One-Minute Takeaway on Pediatric Obesity GLP-1 Therapy
One-Minute Takeaway
- Pediatric obesity GLP-1 therapy now has two FDA-approved options for adolescents 12 years and older: semaglutide 2.4 mg weekly (Wegovy, approved 2022) and liraglutide 3.0 mg daily (Saxenda, approved 2020).
- The pivotal STEP TEENS trial showed mean BMI reduction of 16.1% with semaglutide versus +0.6% with placebo at 68 weeks; the liraglutide adolescent trial showed a more modest BMI standard deviation score reduction of approximately 0.22 units at 56 weeks.
- The AAP 2023 Clinical Practice Guideline recommends offering pharmacotherapy alongside intensive health behavior and lifestyle treatment for adolescents 12 and older with obesity (BMI ≥95th percentile).
- Gastrointestinal adverse effects predominate in adolescents as in adults; serious events including pancreatitis and gallbladder disease are rare but require counseling, and long-term developmental outcome data remain limited.
- Cost, insurance coverage, supply constraints, and equity barriers substantially affect real-world access to pediatric obesity GLP-1 therapy and may attenuate effectiveness compared with trial efficacy.
Why Pediatric Obesity GLP-1 Therapy Matters Now
Pediatric obesity affects approximately 20% of US children and adolescents, with severe obesity (BMI at or above 120% of the 95th percentile) affecting roughly 6%. Childhood obesity substantially raises the risk of adult obesity, type 2 diabetes, dyslipidemia, hypertension, hepatic steatosis, and reduced quality of life.
Until recently, the pharmacologic toolkit for adolescent obesity was extremely limited. Orlistat was the only FDA-approved option for years, with modest efficacy and significant gastrointestinal tolerability issues. Bariatric surgery was reserved for adolescents with severe obesity meeting strict criteria.
The 2020 FDA approval of liraglutide (Saxenda) for adolescent obesity, followed by the 2022 approval of semaglutide (Wegovy), introduced high-efficacy GLP-1 agonists into pediatric practice. Pediatric obesity GLP-1 therapy moved from speculative to mainstream within roughly three years.
The 2023 AAP Clinical Practice Guideline elevated pharmacotherapy from a niche option to a standard component of obesity treatment for adolescents who meet criteria. This represented a marked departure from prior “watchful waiting” approaches.
Yet the evidence base for pediatric obesity GLP-1 therapy, while convincing for short-term efficacy, raises pressing questions about long-term durability, developmental safety, and equitable access. These questions shape how pediatricians counsel families navigating a rapidly evolving treatment landscape.
Pediatric Obesity GLP-1: Evidence Reviewed
The pediatric obesity GLP-1 evidence base centers on two pivotal randomized trials in adolescents—STEP TEENS for semaglutide and the Kelly 2020 trial for liraglutide—set against a substantial adult evidence base and the AAP 2023 Clinical Practice Guideline.
The table below summarizes the highest-quality evidence informing current practice. Adult trials are included for context because adolescent trial sample sizes are smaller and adult efficacy and safety patterns inform extrapolation.
| Source | Design | Population | n | Intervention | Primary Outcome |
|---|---|---|---|---|---|
| STEP TEENS (Weghuber 2022) | Phase 3a RCT | Adolescents 12–18, obesity | 201 | Semaglutide 2.4 mg weekly vs placebo | BMI % change at 68 weeks |
| Kelly 2020 (NN8022-4180) | Phase 3 RCT | Adolescents 12–17, obesity | 251 | Liraglutide 3.0 mg daily vs placebo | BMI standard deviation score at 56 weeks |
| AAP CPG (Hampl 2023) | Clinical practice guideline | Children & adolescents | NR | Multimodal recommendations | Comprehensive obesity management |
| STEP 1 (Wilding 2021) | Phase 3 RCT | Adults with obesity | 1,961 | Semaglutide 2.4 mg weekly vs placebo | Body weight change at 68 weeks (adult comparator) |
| SCALE Obesity (Pi-Sunyer 2015) | Phase 3 RCT | Adults with overweight/obesity | 3,731 | Liraglutide 3.0 mg daily vs placebo | Body weight change at 56 weeks (adult comparator) |
| STEP 1 Extension (Wilding 2022) | Withdrawal extension | Adults from STEP 1 | 327 | Semaglutide discontinuation | Weight regain after stopping |
| Kelly 2013 pilot | Phase 2 RCT | Adolescents with severe obesity | 21 | Exenatide vs placebo | Earlier-generation GLP-1 pediatric data |
Key Findings on Pediatric Obesity GLP-1 by Theme
1. Efficacy Magnitude Differs Substantially Between Drugs
The pivotal STEP TEENS trial randomized 201 adolescents aged 12 to 18 with obesity to once-weekly subcutaneous semaglutide 2.4 mg or placebo, both alongside lifestyle counseling, for 68 weeks. The change in BMI from baseline was -16.1% with semaglutide versus +0.6% with placebo.
Approximately 73% of semaglutide-treated adolescents achieved at least 5% body weight reduction, compared with 18% in the placebo group. Reductions in waist circumference, glycated hemoglobin, lipid markers, and inflammatory biomarkers paralleled the BMI changes.
The Kelly 2020 liraglutide trial randomized 251 adolescents aged 12 to 17 with obesity to once-daily subcutaneous liraglutide 3.0 mg or placebo with lifestyle therapy for 56 weeks. The primary endpoint was change in BMI standard deviation score, which favored liraglutide by approximately 0.22 units (treatment difference -0.17 vs placebo).
Body weight changed by -2.65% with liraglutide versus +2.37% with placebo—a net difference of approximately 5%. The cross-trial comparison thus shows roughly threefold greater BMI reduction with semaglutide than liraglutide, paralleling the relative efficacy seen in adult obesity trials.
2. AAP 2023 Guidance Defines Where Pharmacotherapy Fits
The AAP 2023 Clinical Practice Guideline (Hampl et al, Pediatrics 2023) marked a substantial shift in pediatric obesity management, moving away from prior watchful-waiting approaches.
The guideline recommends intensive health behavior and lifestyle treatment of at least 26 hours of contact over 3 to 12 months as foundational for any child with obesity. Pharmacotherapy “should be offered” alongside this for adolescents 12 and older with obesity (BMI ≥95th percentile).
For children aged 8 to 11 with severe obesity, pharmacotherapy “may be offered” under specialized obesity care. Bariatric surgery evaluation may be considered for adolescents 13 and older with severe obesity (BMI ≥120% of the 95th percentile).
Within this framework, pediatric obesity GLP-1 agonists represent the most evidenced pharmacotherapy class for adolescents aged 12 and above, with semaglutide preferred when efficacy magnitude is the dominant consideration and access is feasible.
Clinical pearl: The AAP 2023 framing places pediatric obesity GLP-1 therapy as one component within a multidisciplinary plan, never as a standalone solution. Intensive lifestyle treatment remains foundational—pharmacotherapy is the additive layer, not a substitute.
3. Adverse Effects and Tolerability
Gastrointestinal adverse effects predominate in both semaglutide and liraglutide trials. In STEP TEENS, GI adverse events occurred in approximately 62% of semaglutide-treated adolescents versus 42% on placebo—primarily nausea, vomiting, diarrhea, and constipation.
Most GI events were mild to moderate and tended to abate over weeks of dose titration. The Kelly 2020 liraglutide trial showed a similar pattern, with GI events in approximately 65% of liraglutide-treated adolescents versus 37% on placebo.
Serious adverse events specifically associated with GLP-1 agonists—pancreatitis, cholelithiasis, gallbladder disease—are rare in adolescent trials, paralleling adult experience. Hypoglycemia is uncommon when GLP-1 agonists are used as monotherapy without insulin or sulfonylureas.
The black-box warning regarding thyroid C-cell tumors derives from rodent data and has not translated to a clear human signal, but it remains in the labeling. Reports of suicidal ideation prompted FDA review across the GLP-1 class; no causal association has been established, though active monitoring continues.
4. Long-Term Durability and Developmental Outcomes
Both pivotal pediatric obesity GLP-1 trials enrolled for fewer than 18 months. Adult extension data inform expectations: STEP 1 extension showed approximately two-thirds of weight regain within one year of semaglutide discontinuation, suggesting that pediatric obesity GLP-1 therapy may need to be conceived as chronic, not time-limited.
Effects on growth, puberty, and bone health in adolescents are not adequately studied. Reassuring short-term data exist from STEP TEENS showing no concerning effect on linear growth velocity over 68 weeks, but truly long-term developmental outcomes—including final adult height, pubertal milestones, and bone mineral density—remain unknown.
Behavioral health outcomes showed signal benefit in trials. Health-related quality-of-life measures generally improved with semaglutide treatment. Effects on disordered eating patterns—both potential benefits and theoretical concerns—have not been characterized in adequately powered adolescent studies.
5. Access, Cost, and Equity Considerations
US list prices for semaglutide (Wegovy) approach $1,300 per month and liraglutide (Saxenda) approaches $1,400 per month. Insurance coverage for pediatric obesity GLP-1 therapy is inconsistent, with many state Medicaid programs covering obesity medications variably and commercial coverage often requiring prior authorization with specific BMI and comorbidity criteria.
Manufacturing supply constraints affected semaglutide availability through 2023 and 2024, particularly impacting newer prescriptions for non-diabetes indications. Compounded versions, while filling supply gaps, raise quality and safety concerns and are not endorsed by the AAP.
The combination of high cost, restricted coverage, and the requirement for chronic administration creates substantial equity concerns. Pediatric populations most affected by obesity—Black, Hispanic, low-income, and rural—face the greatest barriers to access, meaning real-world effectiveness in these populations is likely to lag trial-derived efficacy.
No randomized head-to-head trial of semaglutide vs liraglutide has been conducted in adolescents. Cross-trial comparison shows roughly three-fold greater BMI reduction with semaglutide, but the trials differed in entry criteria, duration, and primary endpoint definitions, so direct comparison is inherently limited.
In adult obesity, the SUSTAIN-7 head-to-head data suggested semaglutide’s greater efficacy at typical doses. Until pediatric head-to-head data emerge, drug selection often turns on weekly vs daily dosing preference, insurance formulary, and access.
The AAP 2023 CPG recommends that pharmacotherapy “should be offered” for adolescents aged 12 and older with obesity (BMI at or above the 95th percentile), in addition to—not instead of—intensive health behavior and lifestyle treatment.
For children aged 8 to 11 with severe obesity, pharmacotherapy “may be offered” under specialized obesity care. Below age 8, GLP-1 agonist use for obesity is not endorsed in current guidance.
This is one of the open questions of pediatric obesity GLP-1 therapy. Available adolescent trial data extend to 56–68 weeks; effects on pubertal trajectory, final adult height, and bone density beyond this window are not characterized.
Current practice generally continues GLP-1 therapy as long as benefit is sustained and tolerability is acceptable, with monitoring of growth velocity, pubertal staging, and laboratory markers. Decisions about pausing or discontinuing therapy are individualized and ideally made in consultation with pediatric endocrinology or specialized obesity care.
Quality and Consistency of Pediatric Obesity GLP-1 Evidence
The pediatric obesity GLP-1 evidence base rests on two phase 3 randomized controlled trials, an extensive adult obesity dataset, and the AAP 2023 guideline synthesis. Consistency between adolescent and adult findings is high for both efficacy and adverse-effect profiles, supporting controlled extrapolation where adolescent data are sparse.
What the Pediatric Obesity GLP-1 Evidence Does Not Show
Several questions central to pediatric obesity GLP-1 clinical decision-making remain unresolved. Naming these gaps explicitly helps clinicians counsel adolescents and families honestly about the limits of current knowledge.
Specific Evidence Gaps
- Long-term durability beyond 18 months in adolescents is unknown; whether weight regain after discontinuation parallels adult experience requires direct study.
- Effects on growth, puberty, and bone health through and beyond pubertal completion have not been prospectively characterized.
- Disordered eating outcomes—both potential benefit (reduced binge eating) and concern (driving restrictive patterns)—are not adequately studied in adolescents.
- Cardiometabolic outcomes in adolescents (incident type 2 diabetes, sustained blood pressure, lipid trajectories) require longer follow-up than current trials provide.
- Head-to-head comparisons of semaglutide vs liraglutide in adolescents are absent; tirzepatide adolescent trials are ongoing but not yet reported.
- Real-world effectiveness in populations with significant access barriers—where prior authorization, copays, and supply chain issues affect treatment continuity—is poorly characterized.
- Pre-pubertal use (under age 12) lacks endorsed evidence; off-label use exists but is not supported by adequately powered trials.
- Optimal lifestyle treatment integration: how the intensive health behavior component should be operationalized when pharmacotherapy is co-prescribed has not been rigorously studied.
These gaps do not undermine the strong short-term evidence; they shape where humility belongs in shared decision-making and where surveillance and ongoing trials will most usefully refine pediatric obesity GLP-1 practice.
Practical Implications for Pediatric Obesity GLP-1 Therapy
Based on the current evidence, pediatric obesity GLP-1 therapy should be approached as one component of a multidisciplinary obesity management plan. The implications below describe what the evidence supports rather than directive prescriptions, and each should be combined with local protocols, formulary realities, and clinical judgment.
Match Drug Choice to Patient Goals
Semaglutide’s greater efficacy magnitude and weekly dosing favor it when access is feasible. Liraglutide may be appropriate when daily dosing or formulary considerations align.
Combine with Intensive Lifestyle Treatment
Pediatric obesity GLP-1 therapy is evidence-supported as an addition to intensive health behavior treatment, not a substitute. The AAP 2023 guidance reinforces this layered approach.
Counsel Proactively on GI Effects
Set expectations for nausea, vomiting, and diarrhea during titration. Most GI symptoms abate over weeks; slow titration and dietary adjustments improve tolerability.
Plan as Chronic Disease Management
Adult data show substantial weight regain within a year of discontinuation. Frame pediatric obesity GLP-1 therapy as long-term management, not a finite course.
Monitor Growth, Puberty, and Behavior
Track linear growth velocity, pubertal staging, mood, and eating-behavior changes. Coordinate with pediatric endocrinology where developmental concerns arise.
Address Access and Equity Actively
Help families navigate prior authorization, manufacturer assistance programs, and supply availability. Document equity-related barriers when treatment cannot be sustained.
A consistent counseling message integrating the evidence: “GLP-1 medications can substantially reduce BMI and improve obesity-related health markers in adolescents when combined with intensive lifestyle treatment. They are most likely to be effective when continued long-term, and they require careful monitoring of side effects and developmental health.”
Evidence Grade and Bottom Line
Evidence Grade: Strong for short-term efficacy of both semaglutide and liraglutide in reducing adolescent BMI. Moderate for medium-term safety and tolerability. Limited for long-term durability, developmental safety, and head-to-head comparison.
The pediatric obesity GLP-1 evidence base meets the threshold for strong evidence for short-term efficacy. Effect-size concordance with the adult dataset reinforces confidence at this tier. The longer-term and developmental questions remain genuinely open.
Bottom Line
- Semaglutide and liraglutide are FDA-approved for adolescent obesity from age 12, with semaglutide producing approximately threefold greater BMI reduction than liraglutide in cross-trial comparison.
- The AAP 2023 Clinical Practice Guideline supports offering pharmacotherapy alongside intensive lifestyle treatment for adolescents with obesity, marking a clear shift from prior watchful-waiting approaches.
- Gastrointestinal effects predominate and are usually manageable with titration; serious adverse events are rare but warrant counseling about pancreatitis, gallbladder disease, and other class-specific concerns.
- Long-term durability data suggest these medications should be conceived as chronic obesity management, with weight regain expected after discontinuation in line with adult experience.
- Cost, insurance coverage, and supply constraints create significant equity barriers that may attenuate real-world effectiveness compared with trial efficacy and disproportionately affect populations most burdened by adolescent obesity.
Article Information and References
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages and approvals should be verified against current prescribing information, which may be updated after publication of this review.
References
- Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med. 2022;387(24):2245–2257. DOI: 10.1056/NEJMoa2208601
- Kelly AS, Auerbach P, Barrientos-Perez M, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382(22):2117–2128. DOI: 10.1056/NEJMoa1916038
- Hampl SE, Hassink SG, Skinner AC, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023;151(2):e2022060640. DOI: 10.1542/peds.2022-060640
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. DOI: 10.1056/NEJMoa2032183
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22. DOI: 10.1056/NEJMoa1411892
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–1564. DOI: 10.1111/dom.14725
- Kelly AS, Metzig AM, Rudser KD, et al. Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study. Obesity. 2012;20(2):364–370. DOI: 10.1038/oby.2011.337
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971–984. DOI: 10.1016/S0140-6736(21)00213-0
- Skinner AC, Ravanbakht SN, Skelton JA, Perrin EM, Armstrong SC. Prevalence of obesity and severe obesity in US children, 1999–2016. Pediatrics. 2018;141(3):e20173459. DOI: 10.1542/peds.2017-3459
- Stierman B, Afful J, Carroll MD, et al. National Health and Nutrition Examination Survey 2017–March 2020 prepandemic data files. National Health Statistics Reports. 2021;158. DOI: 10.15620/cdc:106273
- Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414–1425. DOI: 10.1001/jama.2021.3224
- Kelly AS, Marcus MD, Yanovski JA, Yanovski SZ, Osganian SK. Working toward precision medicine approaches to treat severe obesity in adolescents: report of an NIH workshop. Int J Obes (Lond). 2018;42(11):1834–1844. DOI: 10.1038/s41366-018-0231-x
- Cardel MI, Atkinson MA, Taveras EM, Holm JC, Kelly AS. Obesity treatment among adolescents: a review of current evidence and future directions. JAMA Pediatr. 2020;174(6):609–617. DOI: 10.1001/jamapediatrics.2020.0085
- Sørensen K, Christensen R, Joensen UN, et al. Anti-obesity drugs in children and adolescents: a systematic review and meta-analysis. Lancet Child Adolesc Health. 2024 (in publication track).